BR112019008345A8 - Anticorpos monoclonais ligados à isoforma transmembrana cd160 - Google Patents
Anticorpos monoclonais ligados à isoforma transmembrana cd160Info
- Publication number
- BR112019008345A8 BR112019008345A8 BR112019008345A BR112019008345A BR112019008345A8 BR 112019008345 A8 BR112019008345 A8 BR 112019008345A8 BR 112019008345 A BR112019008345 A BR 112019008345A BR 112019008345 A BR112019008345 A BR 112019008345A BR 112019008345 A8 BR112019008345 A8 BR 112019008345A8
- Authority
- BR
- Brazil
- Prior art keywords
- monoclonal antibodies
- isoform
- antibodies attached
- bind
- transmembrane isoform
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6819—Plant toxins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16306392 | 2016-10-25 | ||
| PCT/EP2017/077261 WO2018077926A1 (en) | 2016-10-25 | 2017-10-25 | Monoclonal antibodies binding to the cd160 transmembrane isoform |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112019008345A2 BR112019008345A2 (pt) | 2019-10-01 |
| BR112019008345A8 true BR112019008345A8 (pt) | 2023-03-07 |
Family
ID=57570549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019008345A BR112019008345A8 (pt) | 2016-10-25 | 2017-10-25 | Anticorpos monoclonais ligados à isoforma transmembrana cd160 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11186635B2 (https=) |
| EP (1) | EP3532502A1 (https=) |
| JP (1) | JP2019535306A (https=) |
| KR (1) | KR20190084264A (https=) |
| CN (1) | CN110121508A (https=) |
| AU (1) | AU2017351764A1 (https=) |
| BR (1) | BR112019008345A8 (https=) |
| CA (1) | CA3080270A1 (https=) |
| WO (1) | WO2018077926A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113614109A (zh) | 2018-12-21 | 2021-11-05 | Ose免疫疗法公司 | 双功能抗pd-1/il-7分子 |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| EP3812008A1 (en) * | 2019-10-23 | 2021-04-28 | Gamamabs Pharma | Amh-competitive antagonist antibody |
| AU2020406083A1 (en) | 2019-12-17 | 2022-06-16 | Boehringer Ingelheim International Gmbh | Bifunctional molecules comprising an IL-7 variant |
| GB202103706D0 (en) * | 2021-03-17 | 2021-04-28 | Ucl Business Ltd | CD160 binding domain |
| EP4320156A1 (en) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| AU2022253351A1 (en) | 2021-04-09 | 2023-10-12 | Boehringer Ingelheim International Gmbh | New scaffold for bifunctional molecules with improved properties |
| US20250179175A1 (en) * | 2022-03-09 | 2025-06-05 | Alderaan Biotechnology | Anti-cd160 transmembrane isoform antibodies |
| WO2024028386A1 (en) | 2022-08-02 | 2024-02-08 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
| CN116350777A (zh) * | 2023-05-17 | 2023-06-30 | 中国人民解放军陆军军医大学 | 麦冬皂苷d自纳米乳在制备肿瘤疫苗佐剂中的应用 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5094941A (en) * | 1987-12-31 | 1992-03-10 | Zymogenetics, Inc. | Monoclonal antibodies to PDGF |
| US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
| ATE120454T1 (de) | 1988-06-14 | 1995-04-15 | Cetus Oncology Corp | Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus. |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| DE69232137T2 (de) | 1991-11-25 | 2002-05-29 | Enzon Inc | Multivalente antigen-bindende proteine |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| DE69434860T2 (de) | 1993-02-22 | 2007-03-15 | The Rockefeller University | Herstellung von helfer-freien retroviren mit hohem titer mittels transienter transfektion |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| FR2712812B1 (fr) | 1993-11-23 | 1996-02-09 | Centre Nat Rech Scient | Composition pour la production de produits thérapeutiques in vivo. |
| US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
| IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| WO1998052976A1 (en) | 1997-05-21 | 1998-11-26 | Biovation Limited | Method for the production of non-immunogenic proteins |
| EP1958962A3 (en) | 1997-06-12 | 2013-05-01 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| EP1176195B1 (en) | 1999-04-09 | 2013-05-22 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| EP2322644A1 (en) | 2000-06-28 | 2011-05-18 | GlycoFi, Inc. | Methods for producing modified glycoproteins |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| WO2003026577A2 (en) | 2001-09-24 | 2003-04-03 | Seattle Genetics, Inc. | P-amidobenzylethers in drug delivery agents |
| HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
| CA2467633C (en) | 2001-12-03 | 2012-03-27 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
| SI1545613T1 (sl) | 2002-07-31 | 2011-11-30 | Seattle Genetics Inc | Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni |
| US7498298B2 (en) | 2003-11-06 | 2009-03-03 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
| EP1718667B1 (en) | 2004-02-23 | 2013-01-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| AU2005218642B2 (en) | 2004-03-02 | 2011-04-28 | Seagen Inc. | Partially loaded antibodies and methods of their conjugation |
| EP1626059A1 (en) | 2004-08-09 | 2006-02-15 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Angiogenic and immunologic applications of anti-CD160 specific compounds obtainable from mAb CL1-R2 |
| WO2006132670A2 (en) | 2004-11-12 | 2006-12-14 | Seattle Genetics, Inc. | Auristatins having an aminobenzoic acid unit at the n terminus |
| EP1898529A1 (en) | 2005-06-28 | 2008-03-12 | Pioneer Corporation | Broadcast receiving apparatus, interference detecting apparatus and interference detecting method |
| HUE035853T2 (en) | 2005-07-18 | 2018-05-28 | Seattle Genetics Inc | Beta-glucuronide-linker-drug conjugates |
| EP1880729A1 (en) | 2006-07-20 | 2008-01-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of soluble CD160 to suppress immunity |
| KR20090088891A (ko) * | 2006-11-15 | 2009-08-20 | 메다렉스, 인코포레이티드 | 비티엘에이에 대한 인간 단일클론 항체 및 이용 방법 |
| EP2006299A1 (en) | 2007-06-18 | 2008-12-24 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Identification of new isoforms of the MHC-class I specific receptor CD160 and uses thereof |
| EP2210903A1 (en) * | 2009-01-21 | 2010-07-28 | Monoclonal Antibodies Therapeutics | Anti-CD160 monoclonal antibodies and uses thereof |
| US20130045871A1 (en) * | 2010-03-18 | 2013-02-21 | Cornell University | Engineering correctly folded antibodies using inner membrane display of twin-arginine translocation intermediates |
| US9045544B2 (en) * | 2010-05-28 | 2015-06-02 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Anti-CD160 specific antibodies for the treatment of eye disorders based on neoangiogenesis |
| US9676871B2 (en) | 2010-11-05 | 2017-06-13 | Pfizer Inc. | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| WO2013072714A1 (en) * | 2011-11-15 | 2013-05-23 | Centre National De La Recherche Scientifique (Cnrs) | Antibodies for molecular imaging of vulnerable plaques in atherosclerosis |
| JP2018508191A (ja) * | 2015-01-16 | 2018-03-29 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | オレキシン受容体１型に対するヒトモノクローナル抗体 |
-
2017
- 2017-10-25 BR BR112019008345A patent/BR112019008345A8/pt not_active Application Discontinuation
- 2017-10-25 JP JP2019542804A patent/JP2019535306A/ja active Pending
- 2017-10-25 KR KR1020197014634A patent/KR20190084264A/ko not_active Ceased
- 2017-10-25 US US16/343,889 patent/US11186635B2/en active Active
- 2017-10-25 CN CN201780080063.4A patent/CN110121508A/zh active Pending
- 2017-10-25 CA CA3080270A patent/CA3080270A1/en not_active Abandoned
- 2017-10-25 AU AU2017351764A patent/AU2017351764A1/en not_active Abandoned
- 2017-10-25 EP EP17797084.5A patent/EP3532502A1/en active Pending
- 2017-10-25 WO PCT/EP2017/077261 patent/WO2018077926A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018077926A1 (en) | 2018-05-03 |
| JP2019535306A (ja) | 2019-12-12 |
| CA3080270A1 (en) | 2018-05-03 |
| CN110121508A (zh) | 2019-08-13 |
| US20190256595A1 (en) | 2019-08-22 |
| AU2017351764A1 (en) | 2019-06-06 |
| EP3532502A1 (en) | 2019-09-04 |
| US11186635B2 (en) | 2021-11-30 |
| KR20190084264A (ko) | 2019-07-16 |
| BR112019008345A2 (pt) | 2019-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019008345A8 (pt) | Anticorpos monoclonais ligados à isoforma transmembrana cd160 | |
| BR112022010206A2 (pt) | Receptores de antígeno quiméricos e usos dos mesmos | |
| MX2022000132A (es) | Inmunoreceptores especificos de claudina-18.2 y epitopos de celulas t. | |
| CO2018010538A2 (es) | Anticuerpos específicos del receptor de poliovirus humano (rvp) | |
| MX2019011927A (es) | Anticuerpos anti-ilt4 y fragmentos de union a antigeno. | |
| CL2017002401A1 (es) | Anticuerpos contra icos | |
| BR112020009759A8 (pt) | Anticorpos específicos para transcrito 3 semelhante à imunoglobulina (ilt3) e usos dos mesmos | |
| CL2017001610A1 (es) | Anticuerpos humanos para hemagglutinina de influenza | |
| PH12018500861A1 (en) | Antibody/t-cell receptor chimeric constructs and uses thereof | |
| AR111400A1 (es) | Inmunoconjugados que comprenden un polipéptido il-2 mutante y un anticuerpo que se une a pd-1 | |
| MX2017000985A (es) | Anticuerpos anti-pd-1. | |
| MX2017001597A (es) | Anticuerpos anti-pd-l1. | |
| CL2016001723A1 (es) | Molécula de anticuerpo que se une al receptor de muerte programada 1 (pd-1) y usos. | |
| MX2018006875A (es) | Formulacion farmaceutica acuosa que comprende el anticuerpo anti receptor de muerte programada l1 (pd-l1) avelumab. | |
| BR112019008494A2 (pt) | anticorpos para pd-1 e usos dos mesmos | |
| CO2017006740A2 (es) | Anticuerpos anti–cd79b | |
| PE20171764A1 (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123 | |
| MX2021012720A (es) | Celulas t de receptor de antigeno quimerico co-estimulador que toman como diana a il13r-alfa-2. | |
| BR112018002844A2 (pt) | receptores de antígeno quimérico à base de anticorpos de domínio único e métodos de uso dos mesmos | |
| MX2018001398A (es) | Anticuerpos monoclonales contra bcma. | |
| MX376026B (es) | Inmunoreceptores especificos de claudina-6 y epitopos de celulas t. | |
| BR112017004270A2 (pt) | complexos de anticorpos solúveis para células t ou ativação e expansão de células nk | |
| BR112016016916A8 (pt) | uso de um anticorpo que se liga à calicreína plasmática ativa para tratamento de angiodema hereditário (hae) | |
| BR112017013690A2 (pt) | célula | |
| BR112017008945A2 (pt) | Anticorpos anti-cs1 e conjugados fármaco- anticorpo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) ; UNIVERSITE DE MONTPELLIER (FR) ; INSTITUT JEAN GODINOT (FR) ; INSTITUT REGIONAL DU CANCER DE MONTPELLIER (FR) ; UNIVERSITE DE PARIS (FR) |
|
| B25D | Requested change of name of applicant approved |
Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) ; UNIVERSITE DE MONTPELLIER (FR) ; INSTITUT JEAN GODINOT (FR) ; INSTITUT REGIONAL DU CANCER DE MONTPELLIER (FR) ; UNIVERSITE PARIS CITE (FR) |
|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |